First compulsory licence applied by Natco for Nexavar

Indian based generic pharma company Natco has applied for the compulsory licence to produce and sell the NEXAVAR(R) which is a patented product of Bayer. Natco has applied for compulsory licence based on the ground of cost of the medicine which is not affordable by indian people.

If the decision comes in favor of Natco, it will open a door for the compulsory licence to many generic pharmaceutical industry and ultimately it will benefit the society at large.

Natco files ANDA for lenalidomide capsules

Natco Pharma, a Hyderabad based pharma major, has filed an abbreviated new drug application (ANDA) with the US FDA for approval to market lenalidomide capsules in 5, 10, 15 and 25 mg strengths prior to the expiration of various US patents. Natco's lenalidomide capsules are the generic version of Celgene Corporation's Revlimid.


Acccording to company they are the first filer with providing paragraph IV certification and therefore will be awarded with 180 day exclusivity.